



MISSISSIPPI DIVISION OF
MEDICAID

**MISSISSIPPI DIVISION OF MEDICAID
Pharmacy & Therapeutics Committee Meeting
Webex Virtual Meeting**

**August 10, 2021
9:00am to 5:00pm**

MINUTES

Committee Members Present:

Brad Gilchrist, PharmD
Clyde E. Glenn, MD
D. Stanley Hartness, MD
Karen Maltby, MD
Deborah Minor, PharmD, Co-Chair
Kim Rodgers, BSP Pharm, RPh
Wilma Wilbanks, RPh, Chair
S. Caleb Williamson, PharmD

CHC Staff Present:

Laureen Biczak, MD
Sarah Boydston, PharmD
Paige Clayton, PharmD
Steve Liles, PharmD

Committee Members Not Present:

James Benjamin Brock, MD
Mack Woo, MD
Spencer Sullivan, MD
Geri Lee Weiland, MD

Division of Medicaid Staff Present:

Terri Kirby RPh, CPM, Pharmacy Director
Gail McCorkle, RPh, Pharmacist III
Dennis R. Smith, RPh, Pharmacist III
Chris A. Yount, MA, PMP, Staff Officer III

Mississippi Pharmacy & Therapeutics Committee Meeting Minutes
August 10, 2021

Attendance Chart:

Committee Member	AUG 2020	OCT 2020	AUG 2021	MAY 2021
Brock	x			
Davis	x	x		
Gilchrist			x	
Glenn	x	x	x	
Hartness	x	x	x	
Maltby	x	x	x	
Minor	x	x	x	
Rodgers	x	x	x	
Sullivan	x	x		
Weiland		x		
Wilbanks		x	x	
Williamson	x	x	x	
Woo	x			

I. Call to Order

Mrs. Wilbanks, chair, called the meeting to order at 9:03a.m. The meeting was held via an online platform using the WebEx platform.

II. Welcome & Introductions

Ms. Terri Kirby, Mississippi Division of Medicaid (DOM) Pharmacy Director, welcomed the Pharmacy & Therapeutics (P&T) Committee and all Change Healthcare. She stated that the governor had recently approved members whose terms began on July 1, 2020, including one new member, Brad Gilchrist. Additionally, she is awaiting approval of the members recommended for reappointment for the term which began on July 1, 2021.

III. Administrative Matters

Mr. Yount reminded guests that advocate presenters are limited to 3 minutes of general comment about a disease, not specific to a drug. He noted that industry presenters are allowed 3 minutes per drug and that he will mute the speaker's audio line when that 3 minute clock runs out.

Ms. Kirby stated that any documents used in the meeting that are not marked confidential and proprietary will be posted on DOM's website (www.medicaid.ms.gov) after the meeting. The minutes for each P&T Committee meeting are posted to the DOM website (www.medicaid.ms.gov) within 30 days of the meeting. The meeting minutes will be posted no later than September 11, 2021. The PDL decisions will be announced no later than September 1, 2021 on the DOM website.

IV. Approval of October 27, 2020 Meeting Minutes

Mrs. Wilbanks asked for additions or corrections to the minutes from the October 27, 2020 meeting. There were no further additions or corrections. The minutes stand approved.

V. PDL Compliance/Generic Percent Report Updates

Dr. Clayton provided an explanation of the PDL Compliance and Generic Percent reports.

A. Dr. Clayton reviewed the PDL Compliance Report; overall compliance for Q2 2021 was 96.2%.

B. Dr. Clayton reviewed the Generic Percent Report; overall generic utilization for Q2 2021 was 88.9%.

VI. Drug Class Announcements

Dr. Clayton reviewed the meeting format. Dr. Clayton announced Second Round Extractions would be accepted after Public Comment.

VII. First Round of Extractions

Change Healthcare recommended that the following new drugs be extracted:

- Antiretrovirals – Cabenuva (cabotegravir/rilpivirine)
- Bladder Relaxant Preparations - Gemtesa (vibegron)
- Cystic Fibrosis Agents - Bronchitol (mannitol)
- Hereditary Angioedema - Orladeyo (berotralstat)
- Hypoglycemia Treatment, Glucagon - Zegalogue (dasiglucagon)
- Lipotropics, Other Non-Statin - Evkeeza (evinacumab-dgnb)
- Miscellaneous - Verquvo (vericiguat)
- Multiple Sclerosis Agents - Kesimpta (ofatumumab)
- Multiple Sclerosis Agents - Ponvory (ponesimod)
- Muscular Dystrophy Agents - Amondys 45 (casimersen)
- Stimulants And Related Agents - Qelbree (viloxazine)

Dr. Williamson asked that Ophthalmic Dry Eye Agents be extracted.

VIII. Public Comments

1. Joseph Chiodo III from Agile Therapeutics spoke in favor of Twirla.
2. Keanna Dandridge from Novartis Pharmaceuticals Corporation spoke in favor of Kesimpta.
3. Andrew Delgado from Bristol Myers Squibb spoke in favor of Onureg.
4. Opeoluwa Fagbemi from Supernus Pharmaceuticals spoke in favor of Qelbree.
5. Kathrin Kucharski from Sarepta spoke in favor of Amondys 45.
6. Jay Mehta from Jazz Pharma spoke in favor of Xywav.
7. Aimee Metzner from ViiV Healthcare spoke in favor of Cabenuva.
8. Ryan Norman from TEVA Pharmaceuticals spoke in favor of Armonair Digihaler and AirDuo Digihaler.
9. Janis Pruett from Myovant spoke in favor of Orgovyx.
10. John Rivituso from Chiesi USA spoke in favor of Bronchitol Inhalation powder.
11. Doug Welch from Merck spoke in favor of Verquvo.

IX. Second Round of Extractions

No Second Round Extractions were made.

X. Motion for All Non-Extracted Categories to be Approved as Proposed

Change Healthcare recommended that the following list of new drugs be approved without extraction:

- Analgesics/Anesthetics – Licart (diclofenac epolamine)
- Analgesic, Opioid- Short Acting - Qdolo (tramadol)
- Anticonvulsants- Elepsia XR (levetiracetam)
- Antineoplastics, Selected Systemic Enzyme Inhibitors - Fotivda (tivozanib), Gavreto (pralsetinib), Inqovi (cedazuridine/decitabine), Onureg

- (azacitidine), Orgovyx (relugolix), Tepmetko (tepotinib), Ukoniq (umbralisib)
- Antiparkinson’s Agents – Ongentys (opicapone)
- Factory Deficiency Products – Sevenfact (coagulation factor VIIa)
- Glucocorticoids (Inhaled) - Airduo Digihaler (fluticasone propionate/salmeterol xinafoate), Armonair Digihaler (fluticasone propionate)
- Hypoglycemics, Insulins and Related Agents – Semglee (insulin glargine, recombinant)
- Select Contraceptive Products - Nextstellis (drospirenone/estetrol), Phexxi (lactic acid/citric acid/potassium bitartrate), Twirla (ethinyl estradiol/levonorgestrel)
- Steroids (Topical), Very High Potency – Impeklo (clobetasol propionate) lotion
- Stimulants and Related Agents, Narcolepsy – Xywav (calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate)

Dr. Hartness moved to accept the non-extracted recommendations. Mr. Rodgers seconded. Votes were taken and the motion was adopted.

Extracted New Drug/New Generic Reviews

A. Cabenuva (cabotegravir/rilpivirine)

Change Healthcare recommended that Cabenuva be made non-preferred in the Antiretroviral, Combination Products - NRTIs category. A robust clinical discussion followed. Dr. Glenn moved to accept the recommendation. Dr. Minor seconded. Votes were taken, and the motion was adopted. If approved by the executive director, this drug’s PDL status will be as follows:

PREFERRED AGENTS	NON-PREFERRED AGENTS
abacavir/lamivudine lamivudine/zidovudine	abacavir/lamivudine/zidovudine CABENUVA (cabotegravir/rilpivirine) COMBIVIR (lamivudine/zidovudine) DOVATO (dolutegravir/lamivudine) EPZICOM (abacavir/lamivudine) JULUCA (dolutegravir/rilpivirine) TRIZIVIR (abacavir/lamivudine/zidovudine)

B. Gemtesa (vibegron)

Change Healthcare recommended that Gemtesa be made non-preferred in the Bladder Relaxant Preparations category. A robust clinical discussion followed. Dr. Hartness moved to accept the recommendation. Mr. Rodgers seconded. Votes were taken, and the motion was adopted. If approved by the executive director, this drug’s PDL status will be as follows:

PREFERRED AGENTS	NON-PREFERRED AGENTS
oxybutynin ER oxybutynin IR solifenacin	darifenacin DETROL (tolterodine) DETROL LA (tolterodine) DITROPAN XL (oxybutynin) GELNIQUE (oxybutynin) GEMTESA (vibegron) MYRBETRIQ (mirabegron) OXYTROL (oxybutynin) tolterodine tolterodine ER TOVIAZ (fesoterodine fumarate) trospium trospium ER VESICARE (solifenacin) VESICARE LS Suspension (solifenacin)

C. Bronchitol (mannitol)

Change Healthcare recommended that Bronchitol be made non-preferred in the Cystic Fibrosis Agents category. A robust clinical discussion followed. Dr. Glenn moved to accept the recommendation. Dr. Williamson seconded. Votes were taken, and the motion was adopted. If approved by the executive director, this drug's PDL status will be as follows:

PREFERRED AGENTS	NON-PREFERRED AGENTS
BETHKIS (tobramycin) KITABIS (tobramycin) tobramycin(generic TOBI)	BRONCHITOL (mannitol) CAYSTON (aztreonam) colistmethate COLY-MYCIN M (colistimethate sodium) KALYDECO (ivacaftor) ORKAMBI (lumacaftor/ivacaftor) PULMOZYME (dornase alfa) SYMDEKO (tezacaftor/ivacaftor) TOBI (tobramycin) TOBI PODHALER (tobramycin) tobramycin (generic Bethkis) tobramycin (generic Kitabis) TRIKAFTA (elexacaftor/ tezacaftor/ivacaftor)\

D. Orladeyo (berotralstat hydrochloride)

Change Healthcare recommended that Orladeyo be made non-preferred in the Hereditary Angioedema category. A robust clinical discussion followed. Dr. Williamson moved to accept the recommendation. Dr. Maltby seconded. Votes were taken, and the motion was adopted. If approved by the executive director, this drug's PDL status will be as follows:

PREFERRED AGENTS	NON-PREFERRED AGENTS
------------------	----------------------

BERINERT (C1 esterase inhibitor)
 CINRYZE VIAL (C1 esterase inhibitor)
 FIRAZYR SYRINGE (icatibant acetate)
 HAEGARDA (C1 esterase inhibitor)
 icatibant
 KALBITOR VIAL (ecallantide)
ORLADEYO (berotralstat hydrochloride)
 RUCONEST VIAL (C1 esterase inhibitor, recombinant)
 TAKHZYRO (lanadelumab-flyo)

E. Zegalogue (dasiglucagon)

Change Healthcare recommended that Zegalogue be made preferred in the Hypoglycemia Treatment, Glucagon category. A robust clinical discussion followed. Dr. Minor moved to accept the recommendation. Dr. Glenn seconded. Votes were taken, and the motion was adopted. If approved by the executive director, this drug's PDL status will be as follows:

PREFERRED AGENTS	NON-PREFERRED AGENTS
BAQSIMI (glucagon) ^{Step Edit} glucagen vial glucagon kit ZEGALOGUE (dasiglucagon) ^{Step Edit}	GVOKE (glucagon)

F. Evkeeza (evinacumab-dgnb)

Change Healthcare recommended that Evkeeza be made non-preferred in the Lipotropics, Other (Non-Statins) category. A robust clinical discussion followed. Dr. Minor moved to accept the recommendation. Dr. Glenn seconded. Votes were taken, and the motion was adopted. If approved by the executive director, this drug's PDL status will be as follows:

PREFERRED AGENTS	NON-PREFERRED AGENTS
ANGIOPOIETIN LIKE 3 INHIBITORS	
	EVKEEZA (evinacumab-dgnb)

G. Verquvo (vericiguat)

Change Healthcare recommended that Verquvo be made non-preferred in the Miscellaneous Brand/Generic category. A robust clinical discussion followed. Dr. Glenn moved to accept the recommendation. Mr. Rodgers seconded. Votes were taken, and the motion was adopted. If approved by the executive director, this drug's PDL status will be as follows:

PREFERRED AGENTS	NON-PREFERRED AGENTS
alprazolam hydroxyzine hcl syrup hydroxyzine pamoate MAKENA (hydroxyprogesterone caproate) megestrol suspension 625mg/5mL	alprazolam ER EVRYSDI (risdiplam) hydroxyprogesterone caproate hydroxyzine hcl tablets

KORLYM (mifepristone)
 MEGACE ES (megestrol)
VERQUVO (vericiguat)
 VISTARIL (hydroxyzine pamoate)

H. Kesimpta (Ofatumumab) and Ponvory (ponesimod)

Change Healthcare recommended that Kesimpta and Ponvory be made non-preferred in the Multiple Sclerosis category. A robust clinical discussion followed. Dr. Hartness moved to accept the recommendation. Mr. Rodgers seconded. Votes were taken, and the motion was adopted. If approved by the executive director, this drug's PDL status will be as follows:

PREFERRED AGENTS	NON-PREFERRED AGENTS
AUBAGIO (teriflunomide) AVONEX (interferon beta-1a) AVONEX PEN (interferon beta-1a) BETASERON (interferon beta-1b) COPAXONE 20mg (glatiramer) dalfampridine GILENYA (fingolimod) REBIF (interferon beta-1a) REBIF REBIDOSE (interferon beta-1a)	AMPYRA (dalfampridine) BAFIERTAM (monomethyl fumarate) COPAXONE 40mg (glatiramer) dimethyl fumarate EXTAVIA (interferon beta-1b) glatiramer GLATOPA (glatiramer) KESIMPTA (ofatumumab) MAVENCLAD (cladribine) MAYZENT (siponimod) OCREVUS (ocrelizumab) PLEGRIDY (interferon beta-1a) PONVORY (ponesimod) TECFIDERA (dimethyl fumarate) VUMERITY (diroximel fumarate) ZEPOSIA (ozanimod)

I. Amondys 45 (casimersen)

Change Healthcare recommended that Amondys 45 be made non-preferred in the Muscular Dystrophy Agents category. A robust clinical discussion followed. Dr. Glenn moved to accept the recommendation. Dr. Williamson seconded. Votes were taken, and the motion was adopted. If approved by the executive director, this drug's PDL status will be as follows:

PREFERRED AGENTS	NON-PREFERRED AGENTS
	AMONDYS 45 (casimersen) EMFLAZA (deflazacort) EXONDYS 51 (eteplirsen) VILTEPSO (viltolarsen) VYONDYS 53 (golodirsen)

J. Qelbree (viloxazine)

Change Healthcare recommended that Qelbree be made non-preferred in the Stimulants and Related Agents, Non-Stimulants category. A robust clinical discussion followed. Dr. Glenn moved to accept the recommendation. Mr. Rodgers seconded. Votes were taken, and the motion was adopted. If approved by the executive director, this drug's PDL status will be as follows:

PREFERRED AGENTS	NON-PREFERRED AGENTS
atomoxetine guanfacine ER Step Edit	clonidine ER INTUNIV (guanfacine ER) QELBREE (viloxazine) STRATTERA (atomoxetine)

K. Ophthalmic, Dry Eye Agents

Change Healthcare recommended that the Ophthalmics, Dry Eye Agents remain unchanged and the new drug, Eysuvis, be made non-preferred. A robust discussion followed. Dr. Williamson stated that a Mississippi practicing optometrist wrote a letter to him asking for Xiidra to be preferred. The provider stated that he would like other preferred agents on the PDL to offer a variety of options. Other Committee members admitted to receiving a letter as well. Mrs. Wilbanks mentioned that she called and notified Mrs. Kirby upon receipt of her letter. The financial review by Change Healthcare ensued. Dr. Minor moved to accept the recommendation. The motion failed to receive a second.

The discussion continued. Dr. Clayton reminded the Committee that an electronic prior authorization for Xiidra is in place. A trial and failure of 4 paid claims of preferred Restasis in 6 months will allow a claim for Xiidra to pay without a written request. The Committee reviewed the financial information presented to them again. Dr. Minor moved to accept the recommendation. Dr. Glenn seconded. Votes were taken. Voting aye: Minor, Glenn, Hartness, Maltby, Gilchrist. Voting nay: Rodgers, Williamson. The motion was adopted by a vote of 5 to 2. If approved by the executive director, this PDL class will be as follows:

PREFERRED AGENTS	NON-PREFERRED AGENTS
RESTASIS droperette (cyclosporine)	CEQUA (cyclosporine 0.09%) EYSUVIS (loteprednol etabonate) RESTASIS Multidose (cyclosporine) XIIDRA (lifitegrast) ^{Smart PA}

XI. Division of Medicaid Update

Mrs. Kirby offered two updates. Synagis season was extended due to the increased incidence of cases of RSV in Summer 2021. Requests will be determined on a case-by-case basis. The updated form can be found on the DOM website. Secondly, Mrs. Kirby reminded the Committee that DOM is

paying for COVID vaccines at the geographically adjusted Medicare rate. All vaccines are open to billing and the boosters will be covered.

XII. New Business-none

XIII. Next Meeting Date – Tuesday, October 19, 2021

XIV. Adjournment

The meeting adjourned at 11:42am.